Loading
NYSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$18.73
+$0.21 · +1.13%
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
Previous close
$18.73
+$0.21 · +1.13%
Regular session · ET · Market data may be delayed.
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
Day range
Current $18.73
52-week range
Current $18.73
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
73
Undervalued
Sentiment
59
Mixed
Risk
23
Moderate Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
Day range
Current $18.73
52-week range
Current $18.73
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.78T JPY | 4.58T JPY | 4.26T JPY | 4.03T JPY | 3.57T JPY |
| Cost of goods sold | 2.34T JPY | 1.58T JPY | 1.43T JPY | 1.24T JPY | 1.11T JPY |
| Gross profit | 2.44T JPY | 3T JPY | 2.83T JPY | 2.78T JPY | 2.46T JPY |
| Research and development | 716.69B JPY | 730.23B JPY | 729.92B JPY | 633.33B JPY | 526.09B JPY |
| Selling, general, and administrative | 1.15T JPY | 1.1T JPY | 1.05T JPY | 997.31B JPY | 886.36B JPY |
| Operating expenses | 1.87T JPY | 2.66T JPY | 2.62T JPY | 2.29T JPY | 2T JPY |
| Interest income | 223.91B JPY | 19.64B JPY | 78.1M JPY | 5.51B JPY | 4.59B JPY |
| Interest expense | 379.14B JPY | 137.31B JPY | 1.06B JPY | 116.97B JPY | 122.43B JPY |
| Depreciation and amortization | 721.13B JPY | 761.4B JPY | 728B JPY | 664.4B JPY | 583.15B JPY |
| Operating income | 573.04B JPY | 342.59B JPY | 214.08B JPY | 490.51B JPY | 460.84B JPY |
| Net income | 203.33B JPY | 107.93B JPY | 144.07B JPY | 317.02B JPY | 230.06B JPY |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
First Trust Value Line Dividend Index FundFVD31.9M0.42%7.63B USD0.62%$47.66+0.13%
VanEck Pharmaceutical ETFPPH28.35M2.77%1.04B USD0.36%$110.49+1.20%
Avantis International Equity ETFAVDE10.34M0.05%19.22B USD0.23%$89.80+0.58%
ActivePassive International Equity ETFAPIE2.84M0.25%1.13B USD0.45%$38.56+0.65%
Vanguard FTSE All-World ex-US ETFVEU2.22M0.00%98.6B USD0.04%$82.82+0.78%
iShares Dynamic Equity Active ETFBDYN1.44M0.05%3.14B USD0.40%$28.1232+0.69%
Adasina Social Justice All Cap Global ETFJSTC1.1M0.37%301.45M USD0.89%$22.80+0.95%
iShares Flexible Equity Active ETFBFLX1.04M0.05%2.19B USD0.40%$26.1102+0.67%First Trust Value Line Dividend Index FundFVDVanEck Pharmaceutical ETFPPHAvantis International Equity ETFAVDEActivePassive International Equity ETFAPIEVanguard FTSE All-World ex-US ETFVEUiShares Dynamic Equity Active ETFBDYNAdasina Social Justice All Cap Global ETFJSTCiShares Flexible Equity Active ETFBFLXAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
